April 18th 2025
Dupilumab (Dupixent) is the first new targeted therapy for CSU in over a decade.
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arizona
View More
Community Practice Connections™: 20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies
View More
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arkansas
View More
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Wisconsin
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Community Practice Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice?
View More
Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer
View More
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
Proliferating Actinic Keratosis
March 7th 2013The redness on this woman's nose represents fairly severe photodamage with extensive actinic keratosis. Use of a topical therapy to achieve clearance of a field of actinic damage can be done with imiquimod, 5-fluorouracil, or ingenol mebutate creams, or diclofenac gel.
Cutaneous Horn Arising From a Seborrheic Keratosis
February 23rd 2013Cutaneous horns can arise on top of: seborrheic keratosis (as in this patient’s case), actinic keratoses, warts, basal and squamous cell carcinomas. Therefore, the lesion-and especially the base-must be submitted for pathologic diagnosis.
Fixed Drug Eruption Caused by Doxycycline
February 6th 2013The morphology of a round, red to purple patch, with or without blistering, is typical of a fixed drug eruption. This entity usually manifests as a solitary spot, but can be multiple. Tetracycline antibiotics and barbiturate sedatives are common causes. This patient had been taking doxycycline.
Condylomata Acuminata (Severe External Genital Warts)
January 28th 2013Condylomata acuminata this extensive are beyond the capacity of all topical therapies. The area was initially treated by carbon dioxide laser ablation, and residual small foci of infection were subsequently treated with topical 5% imiquimod cream.